Most breast cancer patients need chemotherapy after surgery, chemotherapy drugs, chemotherapy leading to ovarian inhibitors can lead to bone loss, plus postmenopausal patients taking aromatase inhibitors, which aggravates bone loss and increases the risk of fracture. After comprehensive treatment of breast cancer patients, bone density should be reviewed, and general bone density of adults is checked for lumbar spine, femoral neck and other major weight-bearing bones. For patients with C2.0 ≤ T value ≤ C1.5, bisphosphonates should be considered for treatment, and for T value < C2.0 treatment with bisphosphonates is strongly recommended, otherwise the risk of bone adverse events will increase significantly. Yongtao Li, Department of Breast Surgery, Xinjiang Cancer Hospital - Zoledronic acid is the best choice among bisphosphonates, although raloxifene is usually well tolerated, there are adverse effects of vasoconstriction symptoms. - Patients with significant changes in the risk of bone loss due to drug therapy (e.g., postmenopausal women treated with aromatase inhibitors) should be monitored annually, and vitamin D levels should be tested in breast cancer patients.